Entity

Time filter

Source Type

New York City, NY, United States

Sherer T.B.,Michael J Fox Foundation For Parkinsons Research
Science Translational Medicine | Year: 2011

Biomarkers for detecting the early stages of Parkinson's disease (PD) could accelerate development of new treatments. Such biomarkers could be used to identify individuals at risk for developing PD, to improve early diagnosis, to track disease progression with precision, and to test the efficacy of new treatments. Although some progress has been made, there are many challenges associated with developing biomarkers for detecting PD in its earliest stages. Source


Trademark
Michael J Fox Foundation For Parkinsons Research | Date: 2011-04-01

Printed matter, namely, newsletters in the field of medical research and Parkinsons Disease; notepads; pens. T-shirts. Promoting public awareness of Parkinsons Disease. Charitable fundraising. Education services, namely, providing seminars in the field of medical research and Parkinsons Disease. Medical research services; scientific research services.


Trademark
Michael J Fox Foundation For Parkinsons Research | Date: 2011-04-01

notepads; pens. Promoting public awareness of Parkinsons Disease. Charitable fundraising. Education services, namely, providing seminars in the field of medical research and Parkinsons Disease. Medical research services; scientific research services.


Goetz C.G.,Rush University Medical Center | Stebbins G.T.,Rush University Medical Center | Chung K.A.,Oregon Health And Science University | Hauser R.A.,University of South Florida | And 11 more authors.
Movement Disorders | Year: 2013

Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo-controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang-Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26-Item Parkinson's Disease Dyskinesia scale (PDD-26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and Clinical Global Impression (severity and change: CGI-S, CGI-C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty-one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI-C, LF, PDD-26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment-related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society. Source


Nalls M.A.,U.S. National Institute on Aging | Pankratz N.,University of Minnesota | Lill C.M.,Max Planck Institute for Molecular Genetics | Lill C.M.,Johannes Gutenberg University Mainz | And 51 more authors.
Nature Genetics | Year: 2014

We conducted a meta-analysis of Parkinson's disease genome-wide association studies using a common set of 7,893,274 variants across 13,708 cases and 95,282 controls. Twenty-six loci were identified as having genome-wide significant association; these and 6 additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls. Of the 32 tested SNPs, 24 replicated, including 6 newly identified loci. Conditional analyses within loci showed that four loci, including GBA, GAK-DGKQ, SNCA and the HLA region, contain a secondary independent risk variant. In total, we identified and replicated 28 independent risk variants for Parkinson's disease across 24 loci. Although the effect of each individual locus was small, risk profile analysis showed substantial cumulative risk in a comparison of the highest and lowest quintiles of genetic risk (odds ratio (OR) = 3.31, 95% confidence interval (CI) = 2.55-4.30; P = 2 × 10-16). We also show six risk loci associated with proximal gene expression or DNA methylation. © 2014 Nature America, Inc. All rights reserved. Source

Discover hidden collaborations